Antibiotics in the clinical pipeline at the end of 2015.
about
A Novel Spiro-Heterocyclic Compound Identified by the Silkworm Infection Model Inhibits Transcription in Staphylococcus aureusA new biphenyl ether derivative produced by Indonesian ascidian-derived Penicillium albobiverticillium.Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design.DXS as a target for structure-based drug design.New approaches to antibiotic discovery.Wild-Type Gyrase A Genotype of Neisseria gonorrhoeae Predicts In Vitro Susceptibility to Ciprofloxacin: A Systematic Review of the Literature and Meta-Analysis.Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs.l-Lysine based lipidated biphenyls as agents with anti-biofilm and anti-inflammatory properties that also inhibit intracellular bacteria.Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.Institutional profile: Community for Open Antimicrobial Drug Discovery - crowdsourcing new antibiotics and antifungals.Actinomycetes: still a source of novel antibiotics.Promysalin Elicits Species-Selective Inhibition of Pseudomonas aeruginosa by Targeting Succinate Dehydrogenase.Developments in Glycopeptide Antibiotics.Synchronous application of antibiotics and essential oils: dual mechanisms of action as a potential solution to antibiotic resistance.The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.Are highly morphed peptide frameworks lurking silently in microbial genomes valuable as next generation antibiotic scaffolds?Diamide Inhibitors of the Bacillus subtilis N-Acetylglucosaminidase LytG That Exhibit Antibacterial Activity.Antimycobacterial Activities of N-Substituted-Glycinyl 1H-1,2,3-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound.A printable hydrogel microarray for drug screening avoids false positives associated with promiscuous aggregating inhibitors.Synthesis and biological evaluation of novel teixobactin analogues.Valgamicin C, a novel cyclic depsipeptide containing the unusual amino acid cleonine, and related valgamicins A, T and V produced by Amycolatopsis sp. ML1-hF4.Virulence of the melioidosis pathogen Burkholderia pseudomallei requires the oxidoreductase membrane protein DsbB.Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria.Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?Optimization of a resazurin-based microplate assay for large-scale compound screenings against Klebsiella pneumoniae.Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremiaPharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future
P2860
Q33600086-3EF2280C-8D8C-4EB9-8BFD-F2EF9B6EE8E5Q36383329-DE527506-22FD-4754-A41E-538AD6F9AC51Q37639825-F520FD83-144B-46A1-BF9A-91ADA06BDAA3Q38668515-09A04DE7-457D-4658-A687-3F0821BC11E8Q39169766-5EFAC518-C6AF-4A1C-8595-99EDE3D5835DQ39240928-F23F1B5A-9F12-45AC-A93D-D745FA3B8E88Q40076286-DA6E77DD-1A27-449E-B82B-F4574B4CB2D2Q40136867-F7D9EAF5-1476-48C0-972B-5EF3412C21B4Q40156484-0559267E-1A37-418A-BE61-0946E41B9B5AQ42335280-E1B59ED6-19EA-4077-ABE4-00A122D38DEEQ46319269-64D798ED-DEAB-4DA0-9916-ED6CB09963FDQ47232961-1BE22C33-798F-447A-8844-0F061C820412Q47715119-9DA9E47B-7FFB-4543-80D7-8F7F3472ECF0Q47741011-43368D38-2344-491B-A25D-A5E11F6A379DQ47744180-85F71FF8-4542-4865-BA9C-A845C2508F7DQ48132456-CF411C24-7AC6-47A9-85E2-E7D29C959D2DQ48225870-1EF6B420-BB3C-419D-96F6-6B6464E392C2Q48250652-CEFF69AE-4F5D-4D6A-B73C-B5FA4CFC333AQ49363191-9C26D552-D0D2-410E-887A-9331DF0E1DE4Q49376250-0A02A74E-106C-43EB-9A1C-9CD402FA4236Q50015659-CD3D75D0-7EA9-4162-9D47-884716E684D1Q50026707-A6C79AB7-2165-45A6-BB5A-878EFF58BCC1Q51028883-93CF8822-ADA3-4717-B1A8-22AB30145C79Q52655525-819214F4-70E2-46DA-B6A5-4B979C361B42Q52749378-4CF8701A-0BF8-41F2-A468-60289D2C5A5CQ53687829-7B6819D9-A330-4179-9345-42ACAB54CF23Q56777538-AD1C0CE0-6E13-406D-B668-A03F7A009D39Q57158690-BFB9AAE3-A488-4142-B7AF-683B8BBDD41E
P2860
Antibiotics in the clinical pipeline at the end of 2015.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Antibiotics in the clinical pipeline at the end of 2015.
@ast
Antibiotics in the clinical pipeline at the end of 2015.
@en
type
label
Antibiotics in the clinical pipeline at the end of 2015.
@ast
Antibiotics in the clinical pipeline at the end of 2015.
@en
prefLabel
Antibiotics in the clinical pipeline at the end of 2015.
@ast
Antibiotics in the clinical pipeline at the end of 2015.
@en
P2860
P50
P356
P1476
Antibiotics in the clinical pipeline at the end of 2015
@en
P2093
Mark At Blaskovich
P2860
P2888
P356
10.1038/JA.2016.72
P577
2016-06-29T00:00:00Z
P6179
1029571922